INDUCTION-Heroin and Other Short-Acting Opioid Dependent Individuals::

buprenorphine sublingual
Day 1: 4mg sublingual initially
If withdrawal symptoms do not subside after two hours, try again. Do not exceed 8 mg
Day 2:
Without withdrawal symptoms-4mg sublingual initially with withdrawal symptoms-Increase, the dose by 4mg
Administer 4mg if symptoms are not relieved for more than 2 hours. Do not exceed 16mg sublingually

buprenorphine/naloxone (Suboxone)
Caution: Only individuals who are dependent on short-acting opioids (such as heroin) and not those who are addicted to long-acting opioids are eligible for buprenorphine/naloxone (Suboxone) induction (e.g., methadone)
Day 1: 4mg/1mg sublingual or 2mg/0.5mg sublingual initially
Under supervision, one may titrate higher in 2-4 mg increments every two hours; the maximum dose is 8 mg/2 mg
Day 2: single daily dose up to 16mg/4mg sublingually

buprenorphine/naloxone (Zubsolv)
Caution: Only individuals who are dependent on short-acting opioids (such as heroin) and not those who are addicted to long-acting opioids are eligible for buprenorphine/naloxone (zubsolv) induction (e.g., methadone)
Day 1: 5.7mg/1.4mg sublingually in divided doses. Initiate with 1.4mg/0.36mg sublingually. Give the remaining dose from Day 1 of up. to 4.2 mg/1.08 mg in doses of 1 to 2 tablets of 1.4 mg/0.36 mg spaced 1.5 to 2 hours apart
Day 2: 8.4mg/1.4mg buccally as a single dose

MAINTENANCE
Suboxone
Target dose: 12-16mg/4mg buprenorphine/naloxone sublingually as a single dose
Range: 16-24mg buprenorphine. Do not exceed 32mg/day
Adjust buprenorphine/naloxone dosage gradually in increments or decreases of 2 mg/0.5 mg or 4 mg/1 mg to a level that keeps the patient in treatment and reduces the signs and symptoms of opioid withdrawal

Bunavail
Target dose: 8.4mg/1.4mg as a single dose
Range: 2.1/0.3mg to 12.6/2.1mg
Adjust the dosage gradually in 2.1/0.3 mg increments or decrements to a level that keeps the patient in treatment and reduces the signs and symptoms of opioid withdrawal

Zubsolv
Target dose: 11.4mg/2.9mg as a single dose
Range: 2.9/0.71mg to 17.2/4.2mg
Adjust the dosage gradually in 1.4/0.36 mg or 2.9/0.71mg increments or decrements to a level that keeps the patient in treatment and reduces the signs and symptoms of opioid withdrawal

Cassipa
Once buprenorphine has been introduced and stabilised at a dosage of 16 mg, start taking 16 mg/4 mg sublingually once a day
Maximum dose: 16mg/4mg per day

Dose Adjustments

Hepatic impairment
Severe-Avoid usage
Moderate-Not appropriate use
Mild-No dosage adjustment needed

Renal impairment
Following IV injection of 0.3 mg of buprenorphine, there were no variations in the pharmacokinetics of the drug between the nine dialysis-dependent patients and the six healthy individuals

Four buprenorphine HCl implants each containing 80 mg of the drug are implanted in the upper arm for a six-month treatment period and they are extracted at the end of the sixth month
Dosage Considerations Intended only for individuals who have developed a tolerance to opioids

For oral: take 25 mg initially, then observe for one hour, then 50 mg one time a day starting on second day
For Intramuscular: administer 380 mg in gluteal muscle each four weeks for maintenance of abstinence

The recommended dose is 20 and 40 mg taken orally
Maintenance dose: 60 to 90mg is taken every 3 times in a week